PET/CT imaging of Mycobacterium tuberculosis infection

被引:81
作者
Ankrah A.O. [1 ,3 ]
van der Werf T.S. [2 ]
de Vries E.F.J. [1 ]
Dierckx R.A.J.O. [1 ]
Sathekge M.M. [3 ]
Glaudemans A.W.J.M. [1 ]
机构
[1] Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, Gronigen
[2] Department of Internal Medicine, Infectious Diseases, and Pulmonary Diseases and Tuberculosis, University Medical Centre Groningen, University of Groningen, Groningen
[3] Department of Nuclear Medicine, University of Pretoria, Pretoria
关键词
!sup]18[!/sup]F-fluoroethylcholine; !sup]68[!/sup]Ga-citrate; 3′-Deoxy-3′-[[!sup]18[!/sup]F]fluoro-l-thymidine; PET/CT; Tuberculosis;
D O I
10.1007/s40336-016-0164-0
中图分类号
学科分类号
摘要
Tuberculosis has a high morbidity and mortality worldwide. Mycobacterium tuberculosis (Mtb) has a complex pathophysiology; it is an aerobic bacillus capable of surviving in anaerobic conditions in a latent state for a very long time before reactivation to active disease. In the latent tuberculosis infection, the individual has no clinical evidence of active disease, but exhibits a hypersensitive response to proteins of Mtb. Only some 5–10 % of latently infected individuals appear to have reactivation of tuberculosis at any one time point after infection, and neither imaging nor immune tests have been shown to predict tuberculosis reactivation reliably. The complex pathology of the organism provides multiple molecular targets for imaging the infection and targeting therapy. Positron emission tomography (PET) integrated with computer tomography (CT) provides a unique opportunity to noninvasively image the whole body for diagnosing, staging and assessing therapy response in many infectious and inflammatory diseases. PET/CT is a powerful noninvasive tool that can rapidly provide three-dimensional views of disease deep within the body and conduct longitudinal assessment over time in one particular patient. Some PET tracers, such as 18F-fluorodeoxyglucose (18F-FDG), have been found to be useful in various infectious diseases for detection, assessing disease activity, staging and monitoring response to therapy. This tracer has also been used for imaging tuberculosis. 18F-FDG PET relies on the glucose uptake of inflammatory cells as a result of the respiratory burst that occurs with infection. Other PET tracers have also been used to image different aspects of the pathology or microbiology of Mtb. The synthesis of the complex cell membrane of the bacilli for example can be imaged with 11C-choline or 18F-fluoroethylcholine PET/CT while the uptake of amino acids during cell growth can be imaged by 3′-deoxy-3′-[18F]fluoro-l-thymidine. PET/CT provides a noninvasive and sensitive method of assessing histopathological information on different aspects of tuberculosis and is already playing a role in the management of tuberculosis. As our understanding of the pathophysiology of tuberculosis increases, the role of PET/CT in the management of this disease would become more important. In this review, we highlight the various tracers that have been used in tuberculosis and explain the underlying mechanisms for their use. © 2016, The Author(s).
引用
收藏
页码:131 / 144
页数:13
相关论文
共 116 条
[1]  
Young D.B., Gideon H.P., Wilkinson R.J., Eliminating latent tuberculosis, Trends Microbiol, 17, 5, pp. 183-188, (2009)
[2]  
Zumla A., Raviglione M., Hafner R., von Reyn C.F., Tuberculosis, N Engl J Med, 368, 8, pp. 745-755, (2013)
[3]  
Zumla A., George A., Sharma V., Herbett R.H., Oxley A., Oliver M., The WHO 2014 global tuberculosis report—further to go, Lancet Global Health, 3, 1, pp. e10-e12, (2015)
[4]  
Hershkovitz I., Donoghue H.D., Minnikin D.E., Besra G.S., Lee O.Y., Gernaey A.M., Et al., Detection and molecular characterization of 9,000-year old Mycobacterium tuberculosis from a Neolithic settlement in the Eastern Mediterranean, PLoS ONE, 3, 10, (2008)
[5]  
Aziz M.A., Wright A., Laszlo A., De Muynck A., Portaels F., Van Deun A., Et al., Epidermiology of antituberculous drug resistance (The Global Project on Anti-tuberculous drug resistance): an updated analysis, Lancet, 368, 9553, pp. 2142-2154, (2006)
[6]  
Zignol M., van Gemert W., Falzon D., Sismondi's C., Glaziou P., Floyd K., Raviglione M., Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010, Bull World Health Organ, 90, 2, pp. 111D-119D, (2012)
[7]  
Ahuja S.D., Ashkin D., Avendano M., Banerjee R., Bauer M., Bayona J.N., Et al., Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients, PLoS Med, 9, 8, (2012)
[8]  
Resch S.C., Salomon J.A., Murray M., Weinstein M.C., Cost-effectiveness of treating multidrug-resistant tuberculosis, PLoS Med, 3, 7, (2006)
[9]  
Dye C., Scheele S., Dolin P., Pathania V., Raviglione M.C., Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. WHO Global Surveillance and Monitoring Project, JAMA, 282, 7, pp. 677-686, (1999)
[10]  
Corbett E.L., Watt C.J., Walker N., Mahar D., Williams B.G., Raviglione M.C., Dye C., The growing burden of tuberculosis: global trends and interactions with the HIV epidemic, Arch Intern Med, 163, 9, pp. 1009-1021, (2003)